CEBPA
CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung. Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage. Location: Nucleus; Nucleus, nucleolus (UniProt). Locus 19q13.11 (HGNC).
- Leukaemia: Open Targets association 0.86 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.85 with myeloproliferative neoplasm (MONDO_0020076)
- Acute myeloid leukaemia: Open Targets association 0.85 with acute myeloid leukaemia (MONDO_0018874); CIViC evidence names this disease
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CEBPA" OR ABSTRACT:"CEBPA" OR TITLE:"CCAAT enhancer binding protein alpha" OR ABSTRACT:"CCAAT enhancer binding protein alpha" OR TITLE:"CCAAT/enhancer-binding protein alpha" OR ABSTRACT:"CCAAT/enhancer-binding protein alpha" OR TITLE:"C/EBP-alpha" OR ABSTRACT:"C/EBP-alpha") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CEBPA, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cebpa.json. Licence CC BY-NC 4.0.